<?xml version='1.0' encoding='utf-8'?>
<document id="27318985"><sentence text="Metabolism study and biological evaluation of bosentan derivatives."><entity charOffset="46-54" id="DDI-PubMed.27318985.s1.e0" text="bosentan" /></sentence><sentence text="Bosentan, the first-in-class drug used in treatment of pulmonary arterial hypertension, is principally metabolized by the cytochromes P450, and it is responsible for cytochromes induction and drug-drug interaction events with moderate to severe consequences" /><sentence text=" A strategy to reduce drug-drug interactions consists of increasing the metabolic stability of the perpetrator, and fluorinated analogues are often designed to block the major sites of metabolism" /><sentence text=" In this paper bosentan analogues were synthesized, and their metabolism and biological activity were evaluated"><entity charOffset="15-23" id="DDI-PubMed.27318985.s4.e0" text="bosentan" /></sentence><sentence text=" All synthesized compounds showed an improved metabolic stability towards CYP2C9, with one maintaining a moderate antagonist effect towards the ETA receptor" /><sentence text=" " /></document>